Holen Sie sich die Stockscreener-App
1.885
4.14%
0.075
Handel nachbörslich:
1.88
-0.005
-0.27%
Aspire Biopharma Holdings Inc Aktie (ASBP) Neueste Nachrichten
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - citizen-times.com
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) - hattiesburgamerican.com
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - vcstar.com
Aspire Biopharma takes delivery of 2M units of BUZZ BOMB - TipRanks
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity - ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - gainesville.com
Aspire Biopharma launches brand redesign for BUZZ BOMB - TipRanks
Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign - standard-journal.com
BUZZ BOMB caffeine gets sleek new look and direct-to-consumer website - Stock Titan
Aspire Biopharma files patent for first sublingual alprazolam powder By Investing.com - Investing.com Nigeria
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of AlprazolamGeneric Xanax(R)for Rapid Anxiety Relief - columbiatribune.com
Aspire Biopharma files patent application for sublingual alprazolam formulation - TipRanks
Aspire Biopharma files patent for first sublingual alprazolam powder - Investing.com
New under-the-tongue Xanax powder aims to calm panic attacks in minutes - Stock Titan
Aspire Biopharma Announces Reverse Stock Split - azcentral.com
Aspire Biopharma Announces Resignation of Board Director - TipRanks
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin - vcstar.com
Aspire Biopharma Holdings sets share limit for stock incentive plan and approves equity award agreements - Investing.com Nigeria
Aspire Biopharma Adopts Equity Plan Limits and Award Agreements - TipRanks
Aspire Biopharma announces 1-for-40 reverse stock split By Investing.com - Investing.com Nigeria
Aspire Biopharma announces 1-for-40 reverse stock split - Investing.com
International Business Times - FinancialContent
Aspire Biopharma names new executive chair - MSN
Aspire Biopharma director Surendra Ajjarapu resigns from board By Investing.com - Investing.com Canada
Aspire Biopharma director Surendra Ajjarapu resigns from board - Investing.com
Aspire Biopharma Approves Key Proposals at Special Meeting - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin – Retail Expects Licensing Negotiations Soon - Stocktwits
FDA feedback clears path for Aspire Biopharma’s heart attack drug By Investing.com - Investing.com Nigeria
Aspire Biopharma Holdings, Inc.Common Stock (NQ: ASBP - FinancialContent
ASBP stock soars 32% after favorable feedback from FDA for its aspirin – retail expects licensing negotiations soon - MSN
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Aspire Biopharma stock soars after FDA meeting clears path for heart attack drug - Investing.com Nigeria
Aspire Biopharma stock soars after FDA meeting clears path for heart attack drug By Investing.com - Investing.com South Africa
2.92%
2.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):